Callis Duffin Kristina, Gottlieb Alice B, Merola Joseph F, Latella John, Garg Amit, Armstrong April W
From the University of Utah, Salt Lake City, Utah; New York Medical College, Valhalla; Hofstra Northwell School of Medicine, Hempstead, New York; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; International Dermatology Outcome Measurers, West Granby, Connecticut; University of Southern California, Los Angeles, California, USA.
K. Callis Duffin MD, MS, University of Utah; A.B. Gottlieb, MD, PhD, Professor of Dermatology, New York Medical College; J.F. Merola, MD, MMSc, Assistant Professor of Dermatology, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; A. Garg, MD, Hofstra Northwell School of Medicine; A.W. Armstrong, MD, MPH, University of Southern California.
J Rheumatol. 2017 May;44(5):701-702. doi: 10.3899/jrheum.170151.
The International Dermatology Outcome Measures (IDEOM) psoriasis working group was established to develop core domains and measurements sets for psoriasis clinical trials and ultimately clinical practice. At the 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, the IDEOM psoriasis group presented an overview of its progress toward developing this psoriasis core domain set. First, it summarized the February 2016 meeting of all involved with the IDEOM, highlighting patient and payer perspectives on outcome measures. Second, the group presented an overview of the consensus process for developing the core domain set for psoriasis, including previous literature reviews, nominal group exercises, and meeting discussions. Future plans include the development of working groups to review candidate measures for at least 2 of the domains, including primary pathophysiologic manifestations and patient-reported outcomes, and Delphi surveys to gain consensus on the final psoriasis core domain set.
国际皮肤病疗效指标（IDEOM）银屑病工作组的成立旨在为银屑病临床试验乃至临床实践制定核心领域和测量集。在银屑病和银屑病关节炎研究与评估小组2016年年会上，IDEOM银屑病小组介绍了其在制定该银屑病核心领域集方面的进展概况。首先，总结了2016年2月与IDEOM相关各方的会议情况，重点介绍了患者和支付方对疗效指标的看法。其次，该小组概述了制定银屑病核心领域集的共识过程，包括以往的文献综述、名义群体法练习和会议讨论。未来计划包括成立工作组，对至少两个领域的候选测量指标进行审查，这些领域包括主要病理生理表现和患者报告的结果，以及开展德尔菲调查，以就最终的银屑病核心领域集达成共识。
